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Abstract
Introduction: 3,4-Methylenedioxymethamphetamine (MDMA, ‘‘ecstasy’’) is a recreational club drug with supposed
neurotoxic effects selectively on the serotonin system. MDMA users consistently exhibit memory dysfunction but there is an
ongoing debate if these deficits are induced mainly by alterations in the prefrontal or mediotemporal cortex, especially the
hippocampus. Thus, we investigated the relation of verbal memory deficits with alterations of regional cerebral brain
glucose metabolism (rMRGlu) in recreational MDMA users.
Methods: Brain glucose metabolism in rest was assessed using 2-deoxy-2-(18F)fluoro-D-glucose positron emission
tomography (18FDG PET) in 19 male recreational users of MDMA and 19 male drug-naı¨ve controls. 18FDG PET data were
correlated with memory performance assessed with a German version of the Rey Auditory Verbal Learning Test.
Results: As previously shown, MDMA users showed significant impairment in verbal declarative memory performance. PET
scans revealed significantly decreased rMRGlu in the bilateral dorsolateral prefrontal and inferior parietal cortex, bilateral
thalamus, right hippocampus, right precuneus, right cerebellum, and pons (at the level of raphe nuclei) of MDMA users.
Among MDMA users, learning and recall were positively correlated with rMRGlu predominantly in bilateral frontal and
parietal brain regions, while recognition was additionally related to rMRGlu in the right mediotemporal and bihemispheric
lateral temporal cortex. Moreover, cumulative lifetime dose of MDMA was negatively correlated with rMRGlu in the left
dorsolateral and bilateral orbital and medial PFC, left inferior parietal and right lateral temporal cortex.
Conclusions: Verbal learning and recall deficits of recreational MDMA users are correlated with glucose hypometabolism in
prefrontal and parietal cortex, while word recognition was additionally correlated with mediotemporal hypometabolism. We
conclude that memory deficits of MDMA users arise from combined fronto-parieto-mediotemporal dysfunction.
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ‘‘ecstasy’’) is
an illicit club drug predominantly used by adolescents and young
adults for its euphoric, stimulant, and empathogenic/entactogenic
properties [1,2]. After cannabis and cocaine, MDMA together
with other amphetamines are the most commonly used illegal
drugs in Europe and worldwide [3,4]. In a recent survey, 5.5% of
the European general population between 15 to 34 years of age
have taken ecstasy at least once, with an estimated number of 7.5
million users [3].
The psychotropic effects of MDMA are mediated primarily
through reversal and inhibition of the serotonin (5-HT) transporter
(5-HTT) [5] leading to a significant increase of 5-HT in the
synaptic cleft [6]. Other central effects include increases of
extracellular dopamine concentrations in the striatum and the
prefrontal cortex [7], glutamate release in the hippocampus [8], an
a massive elevation of peripheral cortisol levels of 150–800% [9].
Numerous animal studies with different species provided
compelling evidence for an impairment of the 5-HT system
following MDMA exposure [6,10,11]. In non-human primates,
MDMA-induced loss of uniquely 5-HT nerve terminals with a
concomitant depletion of up to 95% of 5-HT was observed
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predominantly in frontal and mediotemporal cortical regions,
while other monoamine neurotransmitters such as dopamine or
norepinephrine remained unaffected [12–16]. Early studies
already suggested an impairment of the 5-HT system in human
MDMA users because they display decreased cerebrospinal fluid
(CSF) levels of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-
HIAA)[17,18]. The human neurotoxicity of MDMA was also
supported by the highly consistent finding that at least intense
MDMA users display marked verbal and visuo-spatial memory
deficits [19–27]. Importantly, lowered 5-HIAA CSF levels in
MDMA users have been shown to be correlated with memory
deficits [25,28]. Finally, also electrophysiological studies suggested
alterations of the 5-HT system in regular MDMA users [29–31].
Human imaging studies using 2-deoxy-2-(18F)fluoro-D-glucose
(18FDG) positron emission tomography (PET) showed reduced
metabolism in the left hippocampus [32], in bilateral caudate/
putamen, the left amygdala [33,34], and in the dorsolateral
prefrontal cortex (DLPFC) [35] of MDMA users. Finally, in a
large sample of MDMA users, increased glucose metabolism in the
ventrolateral frontal cortex (Brodman areal [BA] 10) was reported
as well [33].
PET studies using serotonergic radioligands consistently showed
globally reduced 5-HTT binding in chronic MDMA users most
pronounced in mediotemporal and frontal cortices [36–41]. These
findings were confirmed recently, as widespread cortical and
striatal reductions in 5-HTT levels were shown in MDMA users
[42]. In this sample, time of abstinence was positively correlated
with subcortical, but not cortical, 5-HTT binding, suggesting only
a partial neuronal recovery in these subjects. However, another
recent study failed to find alterations of 5-HTT binding in
recreational MDMA users [43]. Also investigations of postsynaptic
5-HT receptors revealed rather inconsistent results. While early
SPECT studies demonstrated decreased cortical 5-HT2A receptor
binding in current MDMA users and an increase of 5-HT2A
receptors in former users [44], recent PET studies reported either
a small decrease [42] or an increase of cortical 5-HT2A receptor
density in current MDMA users [45,46].
Interpreting the neuropsychological profile, it was speculated
that MDMA users have deficits during storage and/or retrieval of
memory information arising from a dysfunction of the medio-
temporal cortex [20,21,47]. Functional magnetic resonance
imaging (fMRI) studies also suggested differences in the activation
of the hippocampus between MDMA users and healthy controls
during working memory tasks and supported the view of a
hippocampal dysfunction in MDMA users [48–52]. However,
further functional imaging studies additionally reported abnor-
malities in the activation of several other brain regions–including
frontal, thalamic, striatal, cingulate, temporolateral, parietal, and
occipital regions–of MDMA users during working memory tasks
[50,52–54]. Neuropsychological evidence additionally points to an
MDMA-related impairment of executive functions such as
impulsivity, decision-making, and recall consistency indicating
frontal dysfunction [27,55,56].
Thus, although memory deficits are the most consistent finding
in MDMA users [57], their neurobiological basis are unclear so
far. Moreover, no study explored cerebral glucose metabolism
assessed by PET in relation to MDMA-related memory deficits
subdivided into different functions such as learning, recall, and
recognition. Therefore, we investigated regional cerebral glucose
metabolism (rMRGlu) and verbal memory performance of
recreational MDMA users and drug-naı¨ve controls by 18FDG
PET and the Rey Auditory Verbal Learning Test (RAVLT).
Subsequently, we correlated rMRGlu with several RAVLT
parameters in both groups separately to determine the origin of
memory dysfunction in MDMA users. The neuropsychological
pattern already published from this sample suggested that frontal
and mediotemporal dysfunction might be involved in the
development of memory deficits [27]. Thus, we expect to find
correlations specifically between decreased rMRGlu in frontal and
temporomedial brain regions and diminished memory perfor-
mance in MDMA users.
Results
Demographics and drug use
Both groups did not significantly differ with respect to age,
handedness, years of education, and verbal intellectual perfor-
mance (Table 1). There were fewer smokers in the drug-naı¨ve
control group compared to the MDMA group and mean cigarettes
per day also differed between both groups (MDMA: 11.668.6 SD;
controls: 3.168.0 SD; T(36) = 3.19, p,.003). The amount of illicit
drug use is presented in Table 2. Importantly, the MDMA group
used predominantly MDMA, while the use of amphetamine,
cocaine, and hallucinogens was only sporadic. However, MDMA
users also revealed a mild to moderate cannabis use. In contrast,
drug-naı¨ve controls did not report any experiences with illicit
drugs.
Verbal Memory
As reported previously from this sample [27], immediate
(supraspan, trial 1) and delayed recall (trial 7), learning perfor-
mance (S trials 1–5), and recall consistency from the RAVLT was
significantly worse in MDMA users compared to controls with
medium to large effect sizes (d = 0.66–1.13, Table 3). Moreover,
MDMA users revealed a slight and non-significant reduction of
verbal recognition, showing, however, a medium effect size.
Previously, we already demonstrated that several indicators of
MDMA use were significantly correlated with memory scores [27].
Brain metabolism
MDMA users showed a significant decrease of resting rMRGlu
in the right and left DLPFC (Figure 1, Table 4). Bilateral frontal
hypometabolism ranged from BA 8, 9, and 10 up to the premotor
cortex (BA 6), showing slightly stronger effects in the right
hemisphere (Figure 1, Table 4). Moreover, a significant decrease
of resting rMRGlu in MDMA users could be demonstrated for the
bilateral inferior parietal cortex (BA 40), as well as in the right
precuneus (BA 7). In addition, the bilateral thalamus showed
significant hypometabolism primarily in areas connected with the
prefrontal cortex (PFC) [58]. The significant cluster including the
right thalamus extended to the right hippocampus. A significant
decrease of rMRGlu could also be shown in the metencephalon
(pons) and mesencephalon (at the level of the rostral raphe nuclei)
as well as in the right posterior cerebellum of the MDMA users
(Figure 1). Increases of rMRGlu in MDMA users were not
significant.
Correlations of brain metabolism with verbal memory
deficits
To investigate the relation of decreased resting rMRGlu with
memory impairment we only investigated positive correlations
between rMRGlu and memory performance (low performance in
conjunction with decreased rMRGlu) in MDMA users (Figure 2
and Table 5).
Supraspan. Within the MDMA-group, low rMRGlu in the
left inferior parietal (BA 40), left premotor (BA 6), left dorsolateral
(BA 8), and left ventrolateral frontal cortex (BA 44, 47) was
Memory and Frontal Hypometabolism in MDMA Users
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significantly correlated with worse performance during the first
RAVLT trial (supraspan).
Learning. Within the MDMA-group, rMRGlu in the right
premotor (BA 6), bilateral dorsolateral prefrontal (BA 8, 9), and
the left inferior frontal cortex (BA 47) was significantly correlated
with the total learning performance in the RAVLT.
Delayed recall. Within the MDMA-group, rMRGlu in the
bilateral dorsolateral and ventrolateral PFC (BA 8, 9, 10), the right
premotor cortex (BA 6), the right inferior parietal cortex (BA 40,
cluster ranges into the occipital parts of BA 39 and BA 19), and the
right superior temporal cortex (BA 13), were significantly positively
correlated with the delayed recall performance in the RAVLT.
Recall consistency. Within the MDMA-group, rMRGlu
only in the right DLPFC (BA 9) was correlated with recall
consistency during the first five RAVLT trials.
Recognition. Within the MDMA-group, rMRGlu in the
bilateral superior temporal cortices (BA 38), the right orbitofrontal
cortex (gyrus rectus, BA 11), the left anterior hippocampus and
parahippocampal gyrus (BA 28) and the left parieto-occipital part
of the angular gyrus (BA 39) was associated with corrected
recognition performance of list A (p(A)) of the RAVLT.
Correlation of MDMA intake and resting rMRGlu
To investigate the impact of cumulative MDMA intake across
lifetime on structural alterations of the brain, we only investigated
Table 1. Demographic data of 19 male recreational MDMA users and 19 male drug-naı¨ve controls (numbers or means and
standard deviations in parentheses).
Total MDMA users Controls Valuea df p
N 38 19 19
Age 23.8 (5.0) 24.2 (5.8) 23.4 (4.3) T = 0.48 36 0.64
Handedness right/left 32/6 16/3 16/3 x2 = 0.00 1 1.0
Smoker/Nonsmoker 20/18 15/4 5/14 x2 = 8.55 1 0.004
Verbal IQ 103.2 (12.7) 100.6 (11.7) 105.7 (13.5) T =21.25 36 0.22
Years of education 12.4 (1.6) 12.3 (1.7) 12.5 (1.5) T =20.30 36 0.77
aT-tests or Chi2-test (with Yates correction) for frequency data.
doi:10.1371/journal.pone.0061234.t001
Table 2. Pattern and amount of illegal drug use: results of the Psychotropic Drug Interview (means and standard deviations in
parentheses).
Drug characteristicsa MDMA users Controls
MDMA Tablets per week 1.97 (2.73) 0.00 (0.00)
Years of use 3.66 (1.95) 0.00 (0.00)
Cumulative dose (tablets) 457.9 (433.9) 0.00 (0.00)
Lifetime peak doseb (tablets) 6.1 (4.7) 0.00 (0.00)
Last consumption (days) 17.4 (14.6); n = 19 0.00 (0.00)
Cannabis Times per week 1.63 (1.62) 0.00 (0.00)
Years of use 3.95 (3.11) 0.00 (0.00)
Cumulative dose (times) 547.1 (502.7) 0.00 (0.00)
Last consumption (days) 11.1 (21.6); n = 16 0.00 (0.00)
Amphetamine Times per week 0.82 (1.31) 0.00 (0.00)
Years of use 3.37 (2.05) 0.00 (0.00)
Cumulative dose (times) 208.5 (279.5) 0.00 (0.00)
Last consumption (days) 38.1 (89.9); n = 17 0.00 (0.00)
Cocaine Times per week 0.04 (0.10) 0.00 (0.00)
Years of use 0.66 (1.70) 0.00 (0.00)
Cumulative dose (times) 4.87 (12.51) 0.00 (0.00)
Last consumption (days) 34.5 (17.2); n = 4 0.00 (0.00)
Hallucinogensc Cumulative dose (times) 23.4 (38.8) 0.00 (0.00)
Last consumption (month) 7.86 (9.37); n = 14 0.00 (0.00)
aConsumption per week, duration of use, and cumulative dose are averaged within the total group. Last consumption is averaged only for persons who used the drug.
In this case, sample size, n, is shown.
bHighest single MDMA dose ever used.
cPrimarily LSD and psilocybin-containing mushrooms were used.
doi:10.1371/journal.pone.0061234.t002
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negative correlations between resting rMRGlu and drug dose
(high consumption corresponding with decreased rMRGlu). Low
rMRGlu was significantly correlated with high cumulative total
dose of MDMA in the left dorsolateral (BA 8) and bilateral orbital
and ventromedial PFC (BA 11, 25) as well as in the left inferior
parietal cortex (BA 40) and the right lateral temporal cortex (BA
20, 37) (Figures 3 and 4, Table 6).
Overlap of glucose hypometabolism, memory deficits,
and drug intake
To investigate if there is an overlap between frontal hypome-
tabolism, memory impairment and MDMA intake in MDMA
users, we overlaid the significant clusters of the MDMA-control
group contrast (rMRGlu hypometabolism in rest) with the
correlation clusters between rMRGlu and delayed recall and
between rMRGlu and MDMA intake in the PMOD 3.0 (PMOD
Technologies, Zu¨rich, Switzerland). All three significant cluster
sets were projected on an FDG PET template drawn from the
control group (Figure 4). Delayed recall was chosen because
MDMA users showed the strongest impairment here.
Glucose hypometabolism of MDMA users strongly overlapped
with positive correlations of rMRGlu and delayed recall in the
bilateral DLPFC (superior/middle frontal gyrus; BA 8/9).
Moreover, there was a triple overlap of MDMA intake, delayed
recall, and hypometabolism in the left DLPFC. Finally, drug
intake and delayed recall correlations with rMRGlu overlapped in
right inferior parietal cortex (BA 40).
Discussion
The aim of this study was to investigate the neurobiological
correlates of memory deficits in currently abstinent recreational
MDMA users. Using 18FDG-PET in rest, we demonstrated that
MDMA users showed a significant reduction of cerebral glucose
metabolism predominantly in the bilateral DLPFC and inferior
parietal cortex, as well as the bilateral thalamus, right hippocam-
pus, right precuneus, right cerebellum, and pons (at the level of
raphe nuclei). In the group of MDMA users, learning and recall
parameters were positively correlated with rMRGlu primarily in
bilateral frontal and parietal brain regions, while word recognition
was additionally related to rMRGlu in the right mediotemporal
and bihemispheric lateral temporal cortex. In addition, cumulative
lifetime dose of MDMA was negatively correlated with rMRGlu in
the left DLPFC, bilateral ventromedial prefrontal and orbitofron-
tal cortex as well as left inferior parietal and right lateral temporal
cortex. Importantly, glucose hypometabolism and rMRGlu
correlations with recall deficits and cumulative MDMA intake
altogether strongly overlapped within the left DLPFC of MDMA
users, indicating that foremost drug-induced changes of the
DLPFC might contribute to memory impairment in MDMA
users.
Regarding affected brain structures in MDMA users, we
replicated several previous findings reporting decreased glucose
metabolism in the DLPFC [35] and hippocampus [32,33] in
MDMA users. Our results are also in line with previous studies
showing changes of serotonergic radioligand binding in prefrontal
and parietal regions [39–41,44], hippocampus [39], and in the
thalamus [37,59] of MDMA users. In contrast, we did not find
decreased rMRGlu in the amygdala and cingulate cortex or
increased rMRGlu in the ventrolateral PFC as reported from the
so far largest sample of MDMA users (n = 93 compared to n = 27
control subjects) [33]. However, our sample might have been
underpowered to detect these additional changes.
Previous studies demonstrated that regional reduction of
cerebral glucose metabolism might result from loss of neuronal
connections and projections [60–62]. As such, the reductions of
cortical rMRGlu in MDMA users might as well be explained by
loss of neuronal connections and projections and thus be
interpreted as a direct neurotoxic effect of the drug, as they were
shown in many pervious animal studies [13,63]. Interestingly, the
thalamic hypometabolism of MDMA users shown here occurred
in anatomical areas that are well connected to frontocortical
regions presenting also hypometabolism [58]. Also the reduction
of glucose metabolism at the brain stem level might be explained
by lesions of the raphe nuclei as a previous study with non-human
primates demonstrated pathological changes specifically in the
dorsal raphe nucleus induced by MDMA [64]. Crucially, the
symmetry of glucose hypometabolism in MDMA users, which
occurred bilaterally in several regions such as the thalamus, frontal
and prefrontal areas as well as the parietal cortex, confirms the
validity and stability of the present results. Furthermore, it
supports the argument of neurotoxicity, as neuronal damages
would be expected to develop spatially nonspecific, thus equally
distributed over both hemispheres [65].
Given that we have only investigated current users with a mean
duration of abstinence of two to three weeks in a cross-sectional
design, it can not be concluded if the reported alterations are
lasting or transitory.
The results from this study confirm our hypothesis that
hypometabolism in the frontal cortex and in the hippocampus is
correlated with verbal memory deficits in recreational MDMA
users. Within the MDMA group, worse working memory
(supraspan) performance was correlated with low rMRGlu inferior
parietal, premotor, dorsolateral, and left ventrolateral PFC. Given
that the supraspan has a strong working memory component [66]
this correlation pattern might indicate a specific or combined
impairment of articulatory rehearsal processes (premotor cortex,
ventrolateral PFC), of the phonological loop (inferior parietal
lobule), and/or the central executive (DLPFC) in MDMA users
Table 3. Performance in the Rey Auditory Verbal Learning Task (RAVLT) of MDMA users and healthy drug-naive controls (means
and standard deviations in parentheses).
MDMA users Controls T df p Cohen’s d
Supraspan (trial 1) 8.1 (2.3) 9.6 (2.0) 22.11 36 0.042 0.66
Learning performance (S trials 1–5) 56.2 (8.2) 64.7 (5.7) 23.71 36 0.001 1.04
Delayed recall (trial 7) 11.2 (2.9) 14.2 (1.0) 24.21 36 0.0002 1.13
Recall consistency, trials 1–5 (in percent) 86.6 (8.6) 95.1 (4.8) 23.77 36 0.001 1.05
Adjusted recognition performance list A (p(A)) 0.85 (0.1) 0.90 (0.1) 21.68 36 0.102 0.53
doi:10.1371/journal.pone.0061234.t003
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Figure 1. Brain regions in which regional glucose metabolism was significantly decreased in 19 recreational MDMA users compared
to 19 drug-naı¨ve healthy controls (p,.005, uncorrected, cluster level .25 voxel, clusters projected on an SPM MRI template).
doi:10.1371/journal.pone.0061234.g001
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[67]. Furthermore, MDMA users showed a correlation of recall
consistency with rMRGlu in the right DLPFC, which is in line
with the view the recall consistency represents an aspect of
executive functions related to the DLPFC [68],
Within the MDMA group, total learning performance was
associated with the right premotor cortex, bilateral dorsolateral
prefrontal, and the left inferior frontal cortex. Therefore, learning
deficits in MDMA users seem to be caused by dysfunction of
frontal encoding or recall processes [69]. Interestingly, acute
MDMA effects also seem to influence middle frontal gyrus (BA 10)
activity leading to verbal memory encoding impairments [70].
The association of delayed recall and rMRGlu showed the
broadest anatomical extension within the MDMA group. Delayed
recall performance was positively correlated with the rMRGlu in a
prefrontal cluster including the bilateral dorsolateral and ventro-
lateral PFC and right premotor cortex. Moreover, a parieto-
temporal cluster including the right inferior parietal cortex and
right superior temporal cortex appeared. Thus, prefrontal and
parieto-temporal areas seem to be involved in the dysfunction of
delayed recall in MDMA users, indicating disturbed memory
formation into–or diminished recall from association cortices,
beyond the shown working memory and frontal encoding and
recall deficits [66].
Corrected recognition performance was associated with
rMRGlu in bilateral superior temporal cortices, right orbitofrontal
cortex (gyrus rectus), left anterior hippocampus and parahippo-
campal gyrus, and left parieto-occipital part of the angular gyrus.
Therefore, particularly reduced recognition performance in
MDMA users might be explained by hippocampal dysfunction
[71]. However, also prefrontal and anterior temporal areas seem
to be involved–areas that were previously linked with recognition
in several PET studies [72].
Notably, most of the areas showing glucose hypometabolism in
MDMA users are part of the two core brain networks: the resting-
state default mode network (DMN; precuneus, lateral temporal
cortex and hippocampus)[73] and its anti-correlated cognitive
Table 4. Brain regions with significant decreased regional glucose metabolism in 19 recreational MDMA users compared to 19
drug-naı¨ve controls (MNI coordinates of maximum significant voxels, p,.005, uncorrected).
z (df 36) Cluster size MNI coordinates Puncorrected Hemisphere Anatomical region Brodmann area
Voxel x,y,z (mm) voxel-level
3.83 257a 24 54 33 0.000 right middle/superior frontal gyrus 8/9
3.77 114b 15 263 33 0.000 right precuneus 7
3.71 139b 21 254 251 0.000 right cerebellum, posterior lobe -
3.44 85 257 251 42 0.000 left inferior parietal lobule 40
3.42 85 212 45 48 0.000 left middle/superior frontal gyrus 8/9
3.37 34 218 66 15 0.000 left superior frontal gyrus 10
3.24 134b 27 224 9 0.001 right thalamus (prefrontal), hippocampus -
3.22 148b 221 215 9 0.001 left thalamus (prefrontal) -
3.15 25 48 266 45 0.001 right inferior parietal lobule 40
3.05 36 239 9 54 0.001 left middle frontal gyrus 6
2.98 63 23 230 224 0.001 left pons, raphe nuclei -
aCluster significant at p,.05 (corrected for multiple testing).
bCluster significant at p,.05 (uncorrected).
doi:10.1371/journal.pone.0061234.t004
Figure 2. Brain regions in which decreased regional glucose metabolism was significantly correlated with low memory
performance in 19 recreational MDMA users (p,.005, uncorrected, cluster level .25 voxel).
doi:10.1371/journal.pone.0061234.g002
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control network (CCN; DLPFC, parietal cortex)[74]. As cognitive
impairment is assumed to reflect altered network connectivity
between the DMN and the CCN, our findings might point to
disrupted DMN-CCN connectivity, which should be further
investigated using resting-state fMRI in MDMA users.
Taken together, the previously postulated dissociation of
prefrontal and hippocampal functions as correlates of memory
deficits in MDMA users, resulting from temporal or hippocampal
dysfunction alone [21,47,49,51], could not be confirmed. In our
sample, verbal learning and recall deficits of MDMA users were
correlated with glucose hypometabolism in the prefrontal, frontal
and parietal cortex, while word recognition was additionally
correlated with mediotemporal hypometabolism. Thus, our
imaging data support the neuropsychology-based hypothesis of a
combined fronto-parieto-mediotemporal dysfunction in abstinent
MDMA users [27,55]. This assumption is in accordance to the
results of early animal studies showing that MDMA-induced
denervation of 5-HT axons in the frontal cortex and hippocampus
display a relatively low regeneration, thus indicating a high
susceptibility of these structures for MDMA neurotoxicity
[13,75,76].
The cumulative total dose of MDMA was negatively correlated
with rMRGlu in the left dorsolateral and bilateral orbital and
ventromedial PFC, left inferior parietal, and right lateral temporal
cortex. This finding is largely in line with a recent study showing
significant correlation of the severity of MDMA, heroin, alcohol,
and cannabis use with rMRGlu in the DLPFC and lateral
temporal cortex of polydrug users [35].
A limitation of this study is the use of subjective reports for
assessing the extent of drug consumption. The reliability of these
reports may be questionable, as they depend on memory function
and are probably influenced by anticipated social expectancies. A
solution of this problem would be a toxicological hair analysis,
which was not available for us at that time. In this regard, our
urine drug screenings are only of restricted advantage, as water
soluble substances such as MDMA can only be analyzed until few
days post exposure [77]. However, in a study that addressed this
problem, a concordance of 91.3 % was found between subjective
reports of drug consumption and toxicological hair analyzes of
MDMA users, indicating an acceptable reliability of such reports
[78]. Collectively, it is a pertinent unsolved problems of
neurotoxicological research, that an objective method to deter-
mine the cumulative lifetime drug consumption is not available to
date [79]. Another key issue of human neurotoxicity studies in
illicit drug users is the high prevalence of polytoxic drug use in this
population. Although, this study included only subjects with a
Table 5. Brain regions in which regional glucose metabolism was positively correlated with memory parameters in 19 recreational
MDMA users (MNI coordinates of maximum significant voxels, p,.005, uncorrected).
z (df 17) Cluster size MNI coordinates Puncorrected Hemisphere Anatomical region Brodmann area
Voxel x,y,z (mm) voxel-level
Supraspan
3.74 56 239 242 54 0.000 left inferior parietal lobule 40
3.44 30 245 18 26 0.000 left inferior frontal gyrus 47
2.99 31 233 23 63 0.001 left middle frontal gyrus 8
2.98 32 60 3 18 0.001 right precentral / inferior frontal gyrus 6/44
Learning performance
4.42 129a 224 15 54 0.000 left middle frontal gyrus 8
3.65 25 21 57 36 0.000 right superior frontal gyrus 9
3.40 49 227 21 224 0.000 left inferior frontal gyrus 47
2.97 28 54 26 51 0.001 right precentral gyrus 6
Delayed recall
4.45 140a 242 30 39 0.000 left middle frontal gyrus 8/9
4.06 56 45 48 0 0.000 right inferior frontal gyrus 10
3.95 235b 57 242 18 0.000 right superior temporal gyrus 13
3.60 139a 21 54 36 0.000 right superior frontal gyrus 9
3.27 70 39 3 30 0.001 right precentral gyrus 6
3.08 36 36 245 54 0.001 right inferior parietal lobule 40
Recall consistency
3.67 30 18 57 30 0.000 right superior frontal gyrus 9
Recognition
4.09 140a 242 9 221 0.000 left superior/middle temporal gyrus 38/21
3.78 153a 6 48 227 0.000 right gyrus rectus 11
3.66 51 220 215 230 0.000 left parahippocampal gyrus/hippocampus 28
3.66 82 245 281 33 0.000 left angular gyrus 39
3.57 94a 45 12 224 0.000 right superior temporal gyrus 38
aCluster significant at p,.05 (uncorrected).
bCluster significant at p,.05 (corrected for multiple testing).
doi:10.1371/journal.pone.0061234.t005
Memory and Frontal Hypometabolism in MDMA Users
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e61234
predominant use of MDMA, these participants also used other
drugs. A retrospective differentiation of single substance effects is
difficult, as the use of the different substances is highly
intercorrelated. In addition, potential protective or potentiating
effects of substance combinations on neurotoxicity limit the
interpretation of such results. Moreover, tobacco use was
significantly more pronounced in MDMA users compared to
controls. Given, that nicotine has considerable effects on brain
networks and cognitive functions [80,81], the modulating effect of
nicotine on our results is not entirely clear although introduction of
smoking as a covariate into the group comparisons did not change
the main results. Finally, the abstinence duration from the
different drugs was highly variable between subjects; however,
the abstinence duration of MDMA, cannabis, cocaine, amphet-
amine and hallucinogens was not systematically correlated with
rMRGlu in the user group.
The availability of biological markers for the central serotoner-
gic system such as 5-HT or 5-HIAA CSF or plasma concentrations
would have been of advantage for the interpretation of our study
results. However, to date such markers have only low validity and
reliability [82]. Using a specific serotonergic radioligand might
have been of additional interest, as alterations of the cerebral
glucose metabolism only reflect global functioning of neuronal
tissue. Also in this case, the reliability and specificity of in
particular 5-HTT PET ligands seem questionable, as they are not
able to reflect global serotonergic functioning [83,84]. Recently,
we developed a novel method employing 18F-altanserin PET in
Figure 3. Brain regions in which decreased regional glucose
metabolism was significantly correlated with high MDMA
cumulative lifetime consumption in 19 recreational MDMA
users (p, 0.005, uncorrected, cluster level .25 voxel).
doi:10.1371/journal.pone.0061234.g003
Figure 4. Brain regions with decreased regional glucose metabolism (red), and correlations of low memory performance (green)
and high cumulative lifetime MDMA use with glucose metabolism (purple) in 19 recreational MDMA users (p,.005, uncorrected,
cluster level .25 voxel, clusters projected on an 18FDG PET template drawn from the controls).
doi:10.1371/journal.pone.0061234.g004
Memory and Frontal Hypometabolism in MDMA Users
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e61234
combination with a dexfenfluramine challenge in order to measure
5-HT release capacity [85], which now provides the first
functional measure for the 5-HT system in humans. Application
of this method to MDMA users will allow the first functional
investigation of the impact of chronic MDMA intake on 5-HT
release capacity.
Conclusion
Our 18FDG PET and neuropsychological data show that verbal
memory deficits are correlated with glucose hypometabolism in
dorsolateral prefrontal and parietal areas of the brains of abstinent
MDMA users. This is especially true for global learning
performance and delayed recall, while recognition is additionally
associated with mediotemporal hypometabolism. Frontal and
parietal areas show the highest overlap of glucose hypometabolism
with impaired memory function and cumulative drug intake. In
conclusion, memory deficits of MDMA users seem to arise from
combined fronto-parieto-mediotemporal dysfunction.
Methods
Ethic Statement
The study was approved by the Ethics Committee of the
Medical Faculty of the University of Bonn. After being informed of
the aim of the study by written and oral description, all
participants gave written informed-consent statements. The study
has been conducted according to the principles expressed in the
Declaration of Helsinki.
Participants
Nineteen male, chronic but currently abstinent users of MDMA
and 19 subjects with no history of illicit drug use were studied (all
of Caucasian ethnicity). All participants were recruited by
advertisements in a techno music magazine. Subjects of the
MDMA group were required to have used MDMA at least 50
times in lifetime and over a period of at least one year. In addition,
the use of MDMA clearly had to dominate the consumption of any
other psychotropic drug and participants should especially have no
substantial previous use of other amphetamine derivatives (e.g.,
methamphetamine) or cocaine. PET scans and neuropsychological
assessments were carried out when participants were abstinent for
at least three days. Inclusion criteria for both groups included
negative drug urine toxicology. Exclusion criteria for both groups
included use of any psychotropic medication, a present psychiatric
disorder, a family history of psychiatric disorders, as well as a
severe somatic disease. None of the participants reported a history
of migraine, epilepsy, or craniocerebral trauma.
Procedure
On the first day the neuropsychological test battery was assessed
in the afternoon (2 p.m.), while on the subsequent day the PET
scan was carried out in the morning (8 a.m.). For the estimation of
verbal intellectual performance, the Mehrfachwahl-Wortschatz-Intelli-
genztest was used [86]. To control for psychiatric disorders, we
conducted a Structured Clinical Interview (SCID-I) interview accord-
ing to Diagnostic and Statistical Manual IV (DSM-IV) procedures.
Drug history and present pattern of psychotropic drug consump-
tion was assessed by the Interview for Psychotropic Drug Consumption
[30]. Afterwards a neuropsychological test battery was applied,
including the RAVLT [27,55]. The whole battery took about 120
minutes; including breaks as needed, and was generally well
tolerated by the participants. During the psychiatric and
neuropsychological assessment, the subjects could ask for a break
at any time.
Verbal memory assessment
Employment of the Verbaler Lern- und Merkfa¨higkeitstest [66]–a
German version of the RAVLT [87]–has been described in detail
before [27]. In brief, the instrument consists of a word list A of 15
nouns (learning list), a second word list B of 15 different nouns
(interference list) and a third list C of 50 nouns which includes all
words of lists A and B as well as 20 new, but semantically- and
phonetically-related words (recognition list). The dependent
variables used here are: supraspan (trial 1), learning performance
(S trials 1–5), recall consistency in percent (according to [88]),
delayed recall (trial 7 after 30 min), and adjusted recognition
performance (p(A)list A according to [89]). p(A) is comparable to the
discrimination performance (d-prime) of the signal detection
theory [90].
Positron Emission Tomography
On the second day, 18FDG PET scans in rest were conducted
according to the European Association of Nuclear Medicine Procedures
Guidelines for Brain Imaging using 18FDG-PET (Version I)[91], using a
whole-body, high-resolution positron emission tomograph (Sie-
mens/ ECAT EXACT 47, with 5.865.865 mm) with 18FDG as
radiotracer. A ten-minute emission scan was started 30 minutes
after injection of 296–370 MBq 18FDG. This was followed by a
five-minute transmission scan using 68germanium. Image recon-
struction was performed due to filtered back projection using a
Hannig-Filter (cut-off frequency of 0.5 cycles), thus leading to 47
transversal layers of 1286128 pixels each and voxel sizes of
2.05962.05963.375 mm. Blood glucose levels were assessed
anterior to the injection of the tracer. Arterialized blood sampling
was used to measure 18FDG in plasma. Subjects were scanned
Table 6. Brain regions in which regional glucose metabolism was negatively correlated with cumulative lifetime dose of MDMA in
19 recreational MDMA users (MNI coordinates of maximum significant voxels, p,.005, uncorrected).
z (df 17) Cluster size MNI coordinates Puncorrected Hemisphere Anatomical region Brodmann area
Voxel x,y,z (mm) voxel-level
3.63 164a 221 36 51 0.000 left superior frontal gyrus 8
3.37 29 54 257 221 0.000 right fusiform/inferior temporal gyrus 37/20
3.05 29 42 242 57 0.001 right inferior parietal lobule 40
3.04 66 26 33 218 0.001 left medial frontal gyrus 11/25
aCluster significant at p,.05 (uncorrected).
doi:10.1371/journal.pone.0061234.t006
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once, under resting conditions (light dimmed, subjects lying, and
eyes closed) during 8:00 and 9:30 a.m., each.
Data Analysis
Age, verbal IQ, years of education, and memory parameters
were analyzed using t-tests for independent samples (SPSS 12,
Chicago, IL). Handedness and the ratio of smokers and non-
smokers were calculated using x2-tests with Yates correction.
PET data were analyzed using Statistical Parametric Mapping 5
(SPM5; Wellcome Functional Imaging Laboratory, London, UK).
According to the convention of the Montreal Neurological Institution
(MNI), the images were spatially normalized using the PET
template provided in SPM5 and subsequently smoothed with an
isotropic Gaussian kernel to 12612612 mm full width at half
maximum (FWHM). The normalized and smoothed images were
adjusted by a proportional scaling (mean to 50, threshold masking
0.8) for the individual global differences in cerebral glucose
metabolism. For voxel-wise comparisons, t-test for independent
samples was used. Voxel-wise correlations were performed to
assess the relationship between changes in rMRGlu and changes
in individual cognitive performance within each group. Because
we would have liked to avoid ‘‘voodoo correlations’’ we did not
correlate memory performance with metabolic rates within
clusters showing significant rMRGlu differences between both
groups [92]. Significance threshold was set at p,0.005 (uncor-
rected, cluster level .25 voxels). Statistical maps were projected
on an MRI T1 structural image template provided by SPM5.
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